{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:32:33Z","timestamp":1761921153466,"version":"3.40.3"},"publisher-location":"Singapore","reference-count":55,"publisher":"Springer Nature Singapore","isbn-type":[{"type":"print","value":"9789819916269"},{"type":"electronic","value":"9789819916276"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-981-99-1627-6_12","type":"book-chapter","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T10:01:43Z","timestamp":1688724103000},"page":"157-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Late Stage of Abnormal Aging: Dementia"],"prefix":"10.1007","author":[{"given":"Shudan","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,8]]},"reference":[{"issue":"12","key":"12_CR1","doi-asserted-by":"publisher","first-page":"7733","DOI":"10.1074\/jbc.M707142200","volume":"283","author":"P Kienlen-Campard","year":"2008","unstructured":"Kienlen-Campard P et al (2008) Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J Biol Chem 283(12):7733\u20137744","journal-title":"J Biol Chem"},{"issue":"5054","key":"12_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256(5054):184\u2013185","journal-title":"Science"},{"key":"12_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1749-6632.2000.tb06356.x","volume":"903","author":"RO Weller","year":"2000","unstructured":"Weller RO et al (2000) Cerebral amyloid angiopathy: accumulation of a beta in interstitial fluid drainage pathways in Alzheimer's disease. Ann N Y Acad Sci 903:110\u2013117","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"12_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.cell.2005.02.008","volume":"120","author":"RE Tanzi","year":"2005","unstructured":"Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120(4):545\u2013555","journal-title":"Cell"},{"issue":"1","key":"12_CR5","doi-asserted-by":"publisher","first-page":"a006304","DOI":"10.1101\/cshperspect.a006304","volume":"2","author":"B De Strooper","year":"2012","unstructured":"De Strooper B, Iwatsubo T, Wolfe MS (2012) Presenilins and \u03b3-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med 2(1):a006304","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"12_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","volume":"21","author":"H Akiyama","year":"2000","unstructured":"Akiyama H et al (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21(3):383\u2013421","journal-title":"Neurobiol Aging"},{"issue":"3","key":"12_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-014-1267-1","volume":"128","author":"M Prinz","year":"2014","unstructured":"Prinz M et al (2014) Microglia: unique and common features with other tissue macrophages. Acta Neuropathol 128(3):319\u2013331","journal-title":"Acta Neuropathol"},{"issue":"7","key":"12_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/archneurol.2009.125","volume":"66","author":"JP Lister","year":"2009","unstructured":"Lister JP, Barnes CA (2009) Neurobiological changes in the hippocampus during normative aging. Arch Neurol 66(7):829\u2013833","journal-title":"Arch Neurol"},{"issue":"11","key":"12_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014123","volume":"5","author":"M-C Lee","year":"2010","unstructured":"Lee M-C et al (2010) Characterisation of the expression of NMDA receptors in human astrocytes. PLoS One 5(11):e14123","journal-title":"PLoS One"},{"issue":"6286","key":"12_CR10","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong S et al (2016) Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science (New York, N.Y.) 352(6286):712\u2013716","journal-title":"Science (New York, N.Y.)"},{"issue":"5134","key":"12_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1126\/science.7901908","volume":"262","author":"JT Coyle","year":"1993","unstructured":"Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science (New York, N.Y.) 262(5134):689\u2013695","journal-title":"Science (New York, N.Y.)"},{"issue":"2","key":"12_CR12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12264-013-1423-y","volume":"30","author":"Z Chen","year":"2014","unstructured":"Chen Z, Zhong C (2014) Oxidative stress in Alzheimer's disease. Neurosci Bull 30(2):271\u2013281","journal-title":"Neurosci Bull"},{"issue":"1","key":"12_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/157015909787602823","volume":"7","author":"B Uttara","year":"2009","unstructured":"Uttara B et al (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 7(1):65\u201374","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"12_CR14","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1007\/s12035-014-9053-6","volume":"53","author":"PK Kamat","year":"2016","unstructured":"Kamat PK et al (2016) Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of Alzheimer's disease: understanding the therapeutics strategies. Mol Neurobiol 53(1):648\u2013661","journal-title":"Mol Neurobiol"},{"issue":"3","key":"12_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0149-7634(94)90052-3","volume":"18","author":"JC de la Torre","year":"1994","unstructured":"de la Torre JC (1994) Impaired brain microcirculation may trigger Alzheimer's disease. Neurosci Biobehav Rev 18(3):397\u2013401","journal-title":"Neurosci Biobehav Rev"},{"key":"12_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1749-6632.2002.tb04816.x","volume":"977","author":"RA Kenny","year":"2002","unstructured":"Kenny RA, Kalaria R, Ballard C (2002) Neurocardiovascular instability in cognitive impairment and dementia. Ann N Y Acad Sci 977:183\u2013195","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"12_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/0006-8993(92)90132-S","volume":"582","author":"JC de la Torre","year":"1992","unstructured":"de la Torre JC et al (1992) Chronic cerebrovascular insufficiency induces dementia-like deficits in aged rats. Brain Res 582(2):186\u2013195","journal-title":"Brain Res"},{"issue":"1","key":"12_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.molbrainres.2005.05.014","volume":"139","author":"H-X Liu","year":"2005","unstructured":"Liu H-X et al (2005) Altered expression of MAP-2, GAP-43, and synaptophysin in the hippocampus of rats with chronic cerebral hypoperfusion correlates with cognitive impairment. Brain Res Mol Brain Res 139(1):169\u2013177","journal-title":"Brain Res Mol Brain Res"},{"issue":"12","key":"12_CR19","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s007020100019","volume":"108","author":"M Sopala","year":"2001","unstructured":"Sopala M, Danysz W (2001) Chronic cerebral hypoperfusion in the rat enhances age-related deficits in spatial memory. J Neural Trans (Vienna, Austria : 1996) 108(12):1445\u20131456","journal-title":"J Neural Trans (Vienna, Austria : 1996)"},{"issue":"1","key":"12_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/msj.20155","volume":"77","author":"DL Dickstein","year":"2010","unstructured":"Dickstein DL et al (2010) Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med 77(1):82\u2013102","journal-title":"Mt Sinai J Med"},{"issue":"3","key":"12_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/JAD-2010-091555","volume":"20","author":"DS Knopman","year":"2010","unstructured":"Knopman DS, Roberts R (2010) Vascular risk factors: imaging and neuropathologic correlates. J Alzheimer's Dis 20(3):699\u2013709","journal-title":"J Alzheimer's Dis"},{"issue":"7","key":"12_CR22","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1074\/jbc.M505179200","volume":"281","author":"Y Ohyama","year":"2006","unstructured":"Ohyama Y et al (2006) Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes. J Biol Chem 281(7):3810\u20133820","journal-title":"J Biol Chem"},{"issue":"4","key":"12_CR23","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3233\/JAD-2008-15412","volume":"15","author":"O Ghribi","year":"2008","unstructured":"Ghribi O (2008) Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. J Alzheimer's Dis 15(4):673\u2013684","journal-title":"J Alzheimer's Dis"},{"issue":"10","key":"12_CR24","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.15252\/embr.201439225","volume":"15","author":"MG Mart\u00edn","year":"2014","unstructured":"Mart\u00edn MG, Pfrieger F, Dotti CG (2014) Cholesterol in brain disease: sometimes determinant and frequently implicated. EMBO Rep 15(10):1036\u20131052","journal-title":"EMBO Rep"},{"key":"12_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cca.2019.01.022","volume":"491","author":"A Zmys\u0142owski","year":"2019","unstructured":"Zmys\u0142owski A, Szterk A (2019) Oxysterols as a biomarker in diseases. Clin Chim Acta 491:103\u2013113","journal-title":"Clin Chim Acta"},{"issue":"10","key":"12_CR26","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1021\/bi0272151","volume":"42","author":"J Dong","year":"2003","unstructured":"Dong J et al (2003) Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42(10):2768\u20132773","journal-title":"Biochemistry"},{"issue":"19","key":"12_CR27","doi-asserted-by":"publisher","first-page":"11065","DOI":"10.1073\/pnas.1832769100","volume":"100","author":"DL Sparks","year":"2003","unstructured":"Sparks DL, Schreurs BG (2003) Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci U S A 100(19):11065\u201311069","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"12_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00005053-195308000-00001","volume":"118","author":"L Goodman","year":"1953","unstructured":"Goodman L (1953) Alzheimer's disease; a clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. J Nerv Ment Dis 118(2):97\u2013130","journal-title":"J Nerv Ment Dis"},{"issue":"s1","key":"12_CR29","doi-asserted-by":"publisher","first-page":"S379","DOI":"10.3233\/JAD-179944","volume":"64","author":"DJR Lane","year":"2018","unstructured":"Lane DJR, Ayton S, Bush AI (2018) Iron and Alzheimer's disease: an update on emerging mechanisms. J Alzheimer's Dis 64(s1):S379\u2013S395","journal-title":"J Alzheimer's Dis"},{"issue":"10","key":"12_CR30","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.neurobiolaging.2014.04.019","volume":"35","author":"J Becerril-Ortega","year":"2014","unstructured":"Becerril-Ortega J et al (2014) Iron overload accelerates neuronal amyloid-\u03b2 production and cognitive impairment in transgenic mice model of Alzheimer's disease. Neurobiol Aging 35(10):2288\u20132301","journal-title":"Neurobiol Aging"},{"issue":"Pt 6","key":"12_CR31","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1042\/BST0361282","volume":"36","author":"JT Rogers","year":"2008","unstructured":"Rogers JT et al (2008) Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. Biochem Soc Trans 36(Pt 6):1282\u20131287","journal-title":"Biochem Soc Trans"},{"key":"12_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/0-387-23226-5_11","volume":"38","author":"C Exley","year":"2005","unstructured":"Exley C (2005) The aluminium-amyloid cascade hypothesis and Alzheimer's disease. Subcell Biochem 38:225\u2013234","journal-title":"Subcell Biochem"},{"issue":"3","key":"12_CR33","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S2213-8587(13)70088-3","volume":"2","author":"GJ Biessels","year":"2014","unstructured":"Biessels GJ et al (2014) Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diab Endocrinol 2(3):246\u2013255","journal-title":"Lancet Diab Endocrinol"},{"issue":"4","key":"12_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.bbadis.2006.10.002","volume":"1772","author":"Y Yang","year":"2007","unstructured":"Yang Y, Herrup K (2007) Cell division in the CNS: protective response or lethal event in post-mitotic neurons? Biochim Biophys Acta 1772(4):457\u2013466","journal-title":"Biochim Biophys Acta"},{"issue":"8000","key":"12_CR35","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","volume":"2","author":"P Davies","year":"1976","unstructured":"Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet (London, England) 2(8000):1403","journal-title":"Lancet (London, England)"},{"issue":"1","key":"12_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","volume":"14","author":"TH Ferreira-Vieira","year":"2016","unstructured":"Ferreira-Vieira TH et al (2016) Alzheimer's disease: targeting the cholinergic system. Curr Neuropharmacol 14(1):101\u2013115","journal-title":"Curr Neuropharmacol"},{"key":"12_CR37","first-page":"CD005593","volume":"1","author":"J Birks","year":"2006","unstructured":"Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 1:CD005593","journal-title":"Cochrane Database Syst Rev"},{"key":"12_CR38","first-page":"CD001191","volume":"2","author":"J Birks","year":"2009","unstructured":"Birks J et al (2009) Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2:CD001191","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"12_CR39","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jalz.2011.05.2353","volume":"7","author":"C Carlson","year":"2011","unstructured":"Carlson C et al (2011) Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement 7(4):396\u2013401","journal-title":"Alzheimers Dement"},{"issue":"15","key":"12_CR40","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1001\/archinte.159.15.1733","volume":"159","author":"J Cohen-Mansfield","year":"1999","unstructured":"Cohen-Mansfield J et al (1999) Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med 159(15):1733\u20131740","journal-title":"Arch Intern Med"},{"issue":"6","key":"12_CR41","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/HJH.0b013e3283603f53","volume":"31","author":"N Levi Marpillat","year":"2013","unstructured":"Levi Marpillat N et al (2013) Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens 31(6):1073\u20131082","journal-title":"J Hypertens"},{"issue":"1","key":"12_CR42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1124\/jpet.106.112102","volume":"320","author":"DK Lahiri","year":"2007","unstructured":"Lahiri DK et al (2007) The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther 320(1):386\u2013396","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"12_CR43","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","volume":"65","author":"AS Fleisher","year":"2008","unstructured":"Fleisher AS et al (2008) Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65(8):1031\u20131038","journal-title":"Arch Neurol"},{"key":"12_CR44","doi-asserted-by":"crossref","unstructured":"Aisen P et al (2004) Clinical data on Alzhemed (TM) after 12 months of treatment in patients with mild to moderate Alzheimer's disease. Neurobiol Aging 25: S20","DOI":"10.1016\/S0197-4580(04)80065-4"},{"key":"12_CR45","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2016.11","volume":"18","author":"L Montoliu-Gaya","year":"2016","unstructured":"Montoliu-Gaya L, Villegas S (2016) Abeta-immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment. Expert Rev Mol Med 18:e13","journal-title":"Expert Rev Mol Med"},{"issue":"11","key":"12_CR46","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1089\/10445490152717550","volume":"20","author":"B Solomon","year":"2001","unstructured":"Solomon B (2001) Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease. DNA Cell Biol 20(11):697\u2013703","journal-title":"DNA Cell Biol"},{"issue":"1","key":"12_CR47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1):46\u201354","journal-title":"Neurology"},{"issue":"6815","key":"12_CR48","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/35050110","volume":"408","author":"C Janus","year":"2000","unstructured":"Janus C et al (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408(6815):979\u2013982","journal-title":"Nature"},{"issue":"2","key":"12_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2217\/imt.11.170","volume":"4","author":"F Panza","year":"2012","unstructured":"Panza F et al (2012) Immunotherapy for Alzheimer's disease: from anti-\u03b2-amyloid to tau-based immunization strategies. Immunotherapy 4(2):213\u2013238","journal-title":"Immunotherapy"},{"issue":"4","key":"12_CR50","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370(4):311\u2013321","journal-title":"N Engl J Med"},{"issue":"1","key":"12_CR51","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1742-4933-10-18","volume":"10","author":"J Moreth","year":"2013","unstructured":"Moreth J, Mavoungou C, Schindowski K (2013) Passive anti-amyloid immunotherapy in Alzheimer's disease: what are the most promising targets? Immun Ageing 10(1):18","journal-title":"Immun Ageing"},{"issue":"4","key":"12_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/alzrt278","volume":"6","author":"E Kontsekova","year":"2014","unstructured":"Kontsekova E et al (2014) First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther 6(4):44","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"12_CR53","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.molmed.2015.03.003","volume":"21","author":"JT Pedersen","year":"2015","unstructured":"Pedersen JT, Sigurdsson EM (2015) Tau immunotherapy for Alzheimer's disease. Trends Mol Med 21(6):394\u2013402","journal-title":"Trends Mol Med"},{"issue":"2","key":"12_CR54","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1471-4159.2004.02155.x","volume":"88","author":"JH Cho","year":"2004","unstructured":"Cho JH, Johnson GV (2004) Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem 88(2):349\u2013358","journal-title":"J Neurochem"},{"issue":"7","key":"12_CR55","doi-asserted-by":"publisher","first-page":"e0158205","DOI":"10.1371\/journal.pone.0158205","volume":"11","author":"HH Hansen","year":"2016","unstructured":"Hansen HH et al (2016) Long-term treatment with liraglutide, a glucagon-like Peptide-1 (GLP-1) receptor agonist, has no effect on \u03b2-amyloid plaque load in two transgenic APP\/PS1 mouse models of Alzheimer's disease. PLoS One 11(7):e0158205","journal-title":"PLoS One"}],"container-title":["Advances in Experimental Medicine and Biology","Cognitive Aging and Brain Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-981-99-1627-6_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T10:04:36Z","timestamp":1688724276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-981-99-1627-6_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9789819916269","9789819916276"],"references-count":55,"URL":"https:\/\/doi.org\/10.1007\/978-981-99-1627-6_12","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"8 July 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}